Vensica Medical

Developer of a needle-free, ultrasound-based drug delivery system for bladder conditions.

Health Tech & Life Sciences
Active
Seed Netanya, Israel Founded 2014
Last updated 2026-07-26
Total raised
$33.2M
Last: Undisclosed Round 2024-10
Stage
Seed
Founded
2014
Headcount
13
HQ
Netanya, Israel
Sector
Health Tech & Life Sciences

About

Vensica Medical is a clinical-stage biotechnology company developing needle-free therapeutic delivery solutions for urologic diseases. The company's proprietary Vibe® platform uses focused ultrasound to enable localized delivery of biologic and small-molecule drugs into the bladder wall. Vensica's lead program, ViXe, combines the Vibe system with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). Vensica's technology aims to provide a minimally invasive, more comfortable, and effective treatment option compared to traditional injections.

Funding history · 6 rounds · $33.2M total

2024-09
E Round $11.0M
★ Israel Biotech Fund
2022-01
D Round $3.0M
★ Merz Therapeutics
2021-10
C Round $16.0M
★ Israel Biotech FundAgrilineLewis PellLaborie Medical Technologies
2017-08
B Round $2.0M
★ Cogentix MedicalAccelmed
2016-06
A Round $500K
2014-07
Seed $700K

Headcount over time

From 3 (2018-09) to 5 (2026-07) · +2 (+67%) · 19 points · source: Finder history + radar grounding
110 2018-09 2026-07

Q&A

What is Vensica Medical's primary focus?
Vensica Medical is a clinical-stage biotechnology company that develops needle-free therapeutic delivery solutions for urologic diseases, utilizing its proprietary Vibe® platform for localized drug delivery into the bladder wall.
When was Vensica Medical founded?
Vensica Medical was founded in 2014.
How many employees does Vensica Medical currently have?
Vensica Medical has 11-50 employees.
What was Vensica Medical's most recent funding round?
Key investors included Israel Biotech Fund (IBF), Merz, and Laborie.
Which investors participated in Vensica Medical's B Round in November 2021?
The B Round in November 2021 included investments from Israel Biotech Fund (IBF) and Laborie.
What is Vensica Medical's lead product program?
Vensica Medical's lead program, ViXe, combines the Vibe system with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB).
What was the amount raised in Vensica Medical's B Round in February 2022?
In February 2022, Vensica Medical raised $20,000,000 in a B Round, with.
What is the core technology behind Vensica Medical's drug delivery system?
Vensica Medical's Vibe® platform uses focused ultrasound to enable localized delivery of biologic and small-molecule drugs into the bladder wall.

Team · 2

Avner Geva
Founder · Founder & CEO
Avi Eftel
Founder · CTO & Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Simulation & ImagingUltrasound
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

hospitalscancerdrug-deliverymedical-devicesurinary-systemcathetersultrasoundoncologyurologyminimally-invasivepain-freetreatmentsbioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitevensica.com
LinkedInlinkedin.com/company/5350087
YouTubeyoutube.com/@VensicaMedical

Identifiers & details

Founded2014
Employees (exact)13
OfficesNew York

Radar intelligence

Patents

EPO2

Web history (Wayback)

Domainvensica.com

Certificate / subdomain footprint

Subdomains5

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515110765
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2014-07-20
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens0
Registry events5 — violation (1), annual_report (2), people (1), shares_capital (1)
Registered addressהגביש 4 נתניה

Recent registry events

DateEvent
2026-04-12עדכון הפרה
2026-04-12דו~ח שנתי-הקצאת מניות
2026-04-12דו~ח שנתי-הסרת דירקטור
2026-04-06עדכון בעלי תפקידים
2026-04-05הגדלה של הון רשום